0001209191-18-057771.txt : 20181108
0001209191-18-057771.hdr.sgml : 20181108
20181108170324
ACCESSION NUMBER: 0001209191-18-057771
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181106
FILED AS OF DATE: 20181108
DATE AS OF CHANGE: 20181108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lloyd-Smith Malcolm
CENTRAL INDEX KEY: 0001557146
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 181170482
MAIL ADDRESS:
STREET 1: 12481 HIGH BLUFF DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-06
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001557146
Lloyd-Smith Malcolm
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Regulatory Officer
Common Stock
2018-11-06
4
M
0
5700
15.45
A
21018
D
Common Stock
2018-11-06
4
S
0
5700
110.0168
D
15318
D
Common Stock
2018-11-07
4
M
0
3300
15.45
A
18618
D
Common Stock
2018-11-07
4
S
0
3300
110.00
D
15318
D
Non-Qualified Stock Option
15.45
2018-11-06
4
M
0
5700
15.45
A
2024-10-01
Common Stock
5700
13256
D
Non-Qualified Stock Option
15.45
2018-11-07
4
M
0
3300
15.45
A
2024-10-01
Common Stock
3300
9956
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Option granted October 1, 2014 and vested 25% upon first anniversary (October 1, 2015) and remaining 75% vested in 36 equal monthly installments beginning November 1, 2015.
/s/ Darin Lippoldt, Attorney-in-Fact
2018-11-08